Ohio Clinical Trials Collaborative Launches at BIO2014, Accelerating Pharmaceutical Innovation in Ohio

Industry Gains Access to Ohio’s Medical Institutions through Single Point of Contact

2014 BIO International Convention

CLEVELAND--()--The Ohio Clinical Trials Collaborative (OCTC) holds market launch at BIO2014 in San Diego, providing pharmaceutical and medical device companies centralized access to Ohio’s premier medical schools and affiliated entities for clinical trial development.

The pharmaceutical industry faces a challenging and expensive process for conduct of clinical trials required to assess the safety and efficacy of promising therapeutics and devices. The OCTC streamlines the contracting, budgeting, approval of human subject use and patient recruitment/enrollment processes so medical discoveries can move to market faster. With financial support from the State of Ohio, its founding members are Case Western Reserve University, The Ohio State University and University of Cincinnati.

“The OCTC will establish Ohio as one of the most efficient and effective states in which to develop new medicines and treatment strategies. Ohio is the only state that has three National Institutes of Health Clinical and Translational Science Awards centers. This concentration of excellence in a single state provides the opportunity to access an exceptionally strong research and clinical trials network to support the pharmaceutical, biotechnology and medical device industries’ development requirements,” said James Chmiel, MD, Chief Executive and Director of the OCTC.

John Peterson, PhD, Global Business Development Director of the OCTC, stated, “We are pleased to launch the OCTC onto the global stage at BIO2014. Biopharmaceutical companies and clinical research organizations now can access our statewide network of premier translational science centers, hospitals, clinical investigators and patient populations through a single contact point.”

About the Ohio Clinical Trials Collaborative

The OCTC is an initiative under Governor John Kasich’s vision of a premier research medical corridor in Ohio that is co-founded by the Clinical and Translational Science Collaborative at Case Western Reserve University, the Center for Clinical and Translational Science at The Ohio State University and the Center for Clinical and Translational Science and Training at the University of Cincinnati. With offices at Case Western Reserve University’s School of Medicine, the OCTC seeks to establish Ohio as one of the most efficient and effective states in which to test new medications and treatment strategies. The OCTC offers economies of scale and unique capacity, leveraging expertise from across the state of Ohio to conduct clinical trials on behalf of industry sponsors. For more information, please go to www.ohioclintrials.org.

Contacts

Ohio Clinical Trials Collaborative
Business Contact:
John Peterson, PhD, 216-368-0180
Global Business Development Director
john.r.peterson@case.edu
or
Media Contact:
Jessica Studeny, 216-368-4692
jes91@case.edu

Contacts

Ohio Clinical Trials Collaborative
Business Contact:
John Peterson, PhD, 216-368-0180
Global Business Development Director
john.r.peterson@case.edu
or
Media Contact:
Jessica Studeny, 216-368-4692
jes91@case.edu